Membranous Nephropathy Companies

Hoffmann-La Roche company's Obinutuzumab (GAZYVA) is showing promising results in clinical trials as a first-line treatment for IMN, potentially offering a more effective and potentially safer alternative to traditional immunosuppressants.

MorphoSys MOR202 (felzartamab) is another B-cell inhibitor undergoing clinical trials for IMN, demonstrating potential for improved efficacy and reduced side effects compared to current treatment options.

Cerium Pharmaceuticals SNP-ACTH (1-39) Gel is in late-stage clinical trials as a potential first-line treatment for IMN. This topical gel offers a non-invasive and potentially safer approach to managing the condition.

AstraZeneca acquires Alexion Pharmaceuticals acquisition strengthens AstraZeneca's position in the rare disease market, including IMN, with Alexion's Soliris® (eculizumab) already established as a treatment option.

List of Membranous Nephropathy Key Companies in the Market

• Abbvie, Inc.


• Allergan Plc.,


• Amgen Inc.


• AstraZeneca Plc


• Hoffmann-La Roche Ltd


• FibroGen


• Pfizer Inc.